Revised Un-audited Financial Results for the quarter ended 30.06.2026.

2 D E C I P H E R Regd Off: A-2, Q2, 5th Floor, Cyber Towers, Hitech City, Machapur, Hyderabad, Shaikpet, Telangana, India, 500081 ) LABS LIMITED Ph: (491)-40-48536100 Url: www.decipherlabsin Mal: decipherlabsitd@gmail.com Formerly Combat Drugs Limited D.L No.TG/15/04/2016-14766/14767 (INN0.L24230TG1986PLC006781 GST:36AAACCE372L17B Date: 13.08.2026 BSE Limited P. J. Towers, Dalal Street, Mumbai — 400001 Dear Sir/ Madam, Unit: Decipher Labs Limited (Scrip Code: 524752) Sub: Revised Outcome of Board Meeting held on 13.08.2026 This is with reference to the submission made by the Company in respect of the Unaudited Financial Results for the quarter ended June 30, 2026, duly approved by the Board of Directors at its meeting held today i.e., August 13, 2026, and submitted to the Exchange in compliance with the aforementioned Regulations. Subsequent to the aforesaid submission, it has been observed a typographical error in the Unaudited Segment Information. Kindly note that there is no other change in the Unaudited Financial Results of the Company for the Quarter ended 30.06.2026. In light of the above, we are enclosing the Revised Unaudited Financial Results of the Company for the Quarter ended 30.06.2026 for your reference. The inadvertent error was unintentional and occurred in the process of finalization and submission of the financial results. The Company expresses its regret for the inconvenience caused and requests the Exchange to kindly take the revised submission on record. This is for the information and records of the Exchange, please Thanking you. Yours Faithfully For Decipher Labs Limited Dalavath Amarsingh ‘Whole Time Director (DIN: 02206249) DECIPHER LABS LIMITI ED. m asorassericoosren) Regdoff: A2, Q2, 5th Floor, Cyber Towers, M ladhapur, Hyderabad, Telangana, India-500081 URL: www decipherlabs.in, email: it fo@decipherlabs.in, Ph: 04029323151 Statement of Unaudited Standalone Financi Resuits For the Quarter Ended 30th June, 2026 Allamountsin< Lakhs, unless otherwise stated Particulars Quarter ended Year ended 30.06.2026 | 3103.20%6 30.06.2025 3103202 Unaudited Audited Unaudited Audited I Revenue from operations 581 6.69 84.65 11354 Il Other income N 011 N 013 il -Total Income (1 + 1) 981 6.80 8465 11367 IV. Expenses Purchase of Stock in trade - 0.0 64.10 64.50 (Changes in inventories of finished goods 040 (0.20) - (0.20) Employee Benefits Expense 545 532 385 17.53 Depreciation expense 045 045 045 1.50) Other expenses 1135 1839 1022 54,0 [Total expenses 17,60 215 78.62 137.51] (Loss) before Exceptional items (I 1V) (7.88) (17.35 603 (23.82) Vi Exceptional items - - - - [Vil_Profit/{Loss) after Exceptional items (V- Vi) (7.88) (17.35) 6.03 (23.89) [Vill Tax expense: (1) Current tax B B B B (2) Deferred tax 004 (0.09) 044 085 IX. Profit/(Loss) for the period (VII-VITl) (7.93) (17.31) 559 (24.68)] [X_Other comprehensive income B B B B [X1. Total comprehensive income for the year (7.93] (731 559 (4.68) Paid Up Equity Share Capital (FV of Rs 10 each) 101000 1,010.00) 101000 1,010.00 XiI. Eaming per equity share (1) Basic 10.08) (0.17) 006 (0.22) (2) Diluted (0.08) (0.17) 006 (022 Notes 1. The operations of the Company relate to two segments viz;, Man, \facturing and Trading of Pharmaceutical drugs and Consultancy services. segment Information: Particulars, Quarter ended Year Ended 30.06.2026 30062025 | 3103.206 Unaudited Unaudited Audited [Segment Revenue a) Manufacturing and Trading of Pharmaceutical drugs 040 s 6750 67.50 b) Consultancy Services 541 569 17.15 26.04 Total Sales 981 6.60 84.65 11351 Less: Inter Segment Revenue - - - Total Revenue from Operations. 981 660 8465 11350 [Segment Result (Profit Before Tax and Interest from each segment) a) Manufacturing and Trading of Pharmaceutical drugs (0.32) (10.07) 481 (14.17)] b) Consultancy Services (7.56] 17.28] 122 19.66) Total (7.88) (1735 603 2383) Less: Interest and exceptional items - - - - [Total Profit before tax (7.85) (1735 6.03 (3.83) Capital employed (Segment assets- segment liabilities) [Segment assets a) Manufacturing and trading of Pharmaceutical drugs 50214 599,57 59500 559,23 b) Consultancy Services 530 - 428 - Total Assets 90734 899,52 1,003.28 89923 [Segment liabilities a) Manufacturing and trading of Pharmaceutical drugs 9121 7547 13896 7547 b) Consultancy Services 5 - , - <) Unallocated liabilities - - - - Total s o121 7547 13896 7547 2. The above results for the quarter ended 30th June 2026 were rev jiewed by the Audit Committee and approved by the Board of Directors| of the Company at their meeting held on 13th Aug 2026. 3. The financial resuits of the Company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies [Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure 4. The Government of India has notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the “New Labour Codes”) - consolidating 29 existing labour laws. The New Labour Codes are effective from November 21, 2025. The Company has estimated no liability for own employees andis in the process of evaluating other possible impacts including for contract workforce. Forand on behalf of the Board Amar Singh Dalavath Place: Hyderabad Whole Time Director Date: 13.08.2026 DIN: 02206249 DECIPHER LABS LIMITED (e t2s230ratssspicooe7s:) Regd.off: A-2, Q2, 5th Floor, Cyber Towers, Madhapur, Hyderabad, Telangana, India - 500081 URL: www.decipherlabs.in, emai info@decipherlabs.in, Ph: 040 29323151 Statement of Unaudited Consolidated Financial Results For the Quarter Ended June 30, 2026 All amounts in X Lakhs, unless otherwise stated Quarter Ended Year Ended Particulars 30.06.2026 31.03.2026 30.06.2025 | 31st March, 2026 Unaudited Unaudited Unaudited Audited I._Revenue from operations 241.39 360.40 292.37 1,405.40 II. Other income 9.75 17.37 112 22.09 UlLTotal revenue (1 +1I) 25113 377.77 293.49 1,427.49 IV. Expenses Purchase of Stock-in-Trade - 0.40 64.10 64.50 Changes in inventories of finished goods 0.40 (0.40) - (0.40) Employee benefits expense 275.96 267.82 47261 1,498.67 Depreciation and amortisation expense 12.89 14.86 1171 5163 Other expenses 180.40 69.93 8730 18158 Total expenses 469.66 352.61 635.72 1,795.98 V. Profit/(Loss) before Exceptional item (Ill - V) (218.52) 25.16 (342.23) (368.49) Vi.Exceptional items - - - - VI, Profit/{Loss) before tax (1ll - IV) (218.52) 25.16 (342.23) (368.49) VIII. Tax expense: (1) Current tax - - - - (2) Deferred tax 0.04 (60.95) 0.44 (60.06) IX. Profit/(Loss) for the period (V-VI) (218.57) (35.79) (342.67) (308.43) X. Other comprehensive income Items that will be reclassified to statement of profit and loss - , , , Exchange differences on translating the financial statements of foreign Subsidiaries 25.46 88.55 2845 89.37 XI. Total comprehensive income for the year (193.11)) 52.76 (314.22) (219.06) Net Profit/(Loss) for the year attributable to: Owners of the parent (218.57) 86.11 (342.67) (308.43) Non-Controlling Interests - , , , Other Comprehensive Income attributable to: Owners of the parent 2546 88.55 2845 89.37 Non-Controlling Interests - , 5 5 Total Comprehensive Income attributable to: Owners of the parent (193.10) 174.66 (314.22) (219.06) Non-Controlling Interests - 5 5 5 Paid Up Equity Share Capital (FV of Rs 10 each) 1,010.00 1,010.00| _1,010.00 T,010.00 Director (1) Basic (2.16) (0.35) (3.39) (3.05) (2) Diluted (2.16) 10.35) 3.39) (3.05) Notes 1. The operations of the Group relate to two segments viz;, Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services. Segment Information: Quarter Ended Year Ended Particulars 30.06.2026 31.03.2026 30.06.2025 31.03.2026 Unaudited Unaudited Unaudited Audited Segment Revenue: a) Manufacturing and Trading of Pharmaceutical drugs 0. [Showing first 8,000 characters — download PDF for full document]